Tremelimumab

Tremelimumab
	Fab fragment of tremelimumab (blue) binding CTLA-4 (green). From PDB entry 5GGV.
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	CTLA-4
Clinical data
Trade names	Imjudo
Other names	tremelimumab-actl, ticilimumab, CP-675, CP-675,206
AHFS/Drugs.com	Monograph
MedlinePlus	a622078
License data	US DailyMed: Tremelimumab;
Pregnancy; category	AU: D;
Routes of; administration	Intravenous
Drug class	Antineoplastic agent
ATC code	L01FX20 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	745013-59-6 ;
IUPHAR/BPS	8462;
DrugBank	DB11771 ;
ChemSpider	none;
UNII	QEN1X95CIX;
KEGG	D06657;
Chemical and physical data
Formula	C6500H9974N1726O2026S52
Molar mass	146382.47 g·mol−1
	(what is this?) (verify)

Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma (a type of liver cancer). Tremelimumab is designed to attach to and block CTLA-4, a protein that controls the activity of T cells, which are part of the immune system (the body’s natural defenses).

The most common side effects when used in combination with durvalumab include rash, pruritus (itching), diarrhea, abdominal (belly) pain, increased levels of liver enzymes, fever, hypothyroidism (an underactive thyroid gland), cough, peripheral edema (swelling especially of the ankles and feet) and increased level of lipase (an enzyme that helps digest fat, mainly made in the pancreas).

Tremelimumab was approved for medical use in the United States in October 2022, and in the European Union in February 2023.